logo-loader

Algernon Pharma hits milestone in Phase 2b/3 human study of Ifenprodil enrolling 154th patient

Published: 11:55 23 Nov 2020 EST

Algernon Pharmaceuticals (CSE:AGN-OTCQB: AGNPF) CEO Christopher Moreau joined Steve Darling from Proactive to bring news the company has now enrolled 154 patients in its multinational Phase 2b/3 human study of Ifenprodil) for the treatment of COVID-19.

Moreau telling Proactive they have increased the number of patients involved in the study and also gave some details about how the study is being conducted.

Xeris Biopharma Surpasses 2023 Expectations with Strategic Moves Poised for...

Xeris Biopharma CEO Paul Edick joined Steve Darling from Proactive to share news the company had a successful 2023, with a final tally of 164 million USD, which is at the upper end of their forecast. The company concluded the year with 72 million USD in cash, surpassing their initial projections...

11 hours, 35 minutes ago